ASKA Pharmaceutical HoldingsASKA Pharmaceutical Holdings CO., Ltd.4886東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
About 90% of ASKA Pharmaceutical Holdings's sales come from pharmaceutical business, with animal health business and Other making up much of the rest.
Out of every ¥100 of sales, about ¥9 is left as operating profit.
For every ¥100 ASKA Pharmaceutical Holdings sells, how much goes where, and how much is kept.
Margin funnel (derived from reported values)Gross margin 46.6% → Operating margin 8.5% → Net margin 7.6%
Revenue by business segment, and the profit each one keeps.
※ Segment figures include inter-segment sales and do not sum to the company total
EDINET (FSA Japan)
有価証券報告書－第5期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第3期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第2期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第1期(令和3年4月1日－令和4年3月31日)
Extracted from XBRL: 50 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.